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Women attending ante-natal clinic in Nigeria are routinely screened for HIV/AIDS. A retrospective study 
was conducted between 2000 and 2004 to investigate the prevalence of the human immunodeficiency 
virus (HIV) infection among pregnant women attending ante-natal clinic in Braithwalte Memorial 
Hospital (BMH), Port Harcourt, Nigeria. Data on positive cases of HIV infection within the duration were 
retrieved from the hospital’s record department. A total of 10,032 pregnant women were screened for 
the possible occurrence of HIV 1 and HIV 2 within the period. The results shows that a total of 595 
(5.93%) of the pregnant women tested positive to the HIV. The year 2001 had the highest prevalence of 
138 (1.38%), while the year 2000 had the least prevalence of 89 (0.89%). Analysis of the age distribution 
of the infection among the studied pregnant women in the hospital showed that women in the age 
group of 41-45 had the highest prevalence rate (80%), followed by women in the age group of 31-35 with 
an occurrence rate of 20.83%. The least rate of occurrence was observed in the age group of 26-30 
which showed only 3.14%.  
 





The human immunodeficiency virus (HIV) was disco-
vered in 1983 (two years after the diseases AIDS was 
decribed) when Barre-sinousi Montagnier and colleagues 
at the Institute Pasteur, Paris, France, isolated the virus 
from the T cells of a patient with generalized lympha-
denopathy and gave it the name Lymphadenopathy  
associated virus (LAV, now HIV1.). In the same year, 
Robert Gallo and colleagues, working at the National 
Cancer Institute (NCI), USA made a similar discovery 
while in their quest to find cancer-causing viruses. In 
1986 a second closely related virus, termed HIV 2 was 
isolated from a patient from West Africa suffering from 
acquired immunodeficiency syndrome (AIDS) (Adler, 
1992; Hardie, 1999; Noel, 2005). In just over two deca-
des the virus has killed more than 20 million humans and 
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infected over 42 million people globally with the latest 
yearly infection rate of over 6 million (Mahender, 2006).  
HIV is one of several complex retroviruses in the genus 
lentivirus. The virus contains three genes required for a 
replicating retrovirus-gag, pol and env. About three 
additional genes regulate viral expression and are 
important in disease pathogenesis in vivo (Brooks et al., 
2002). These other gene products include the Tat, Rev, 
and Nef regulatory proteins that are translated from 
spliced mRNA species. The HIV structure consist of a 
lipoprotein surface studded by about 72 envelop knobs 
consisting of the glycoproteins gp120, the surfaces (SU) 
protein  and gp41, the transmembrane (TM) protein. Insi-
de this lipid bilayer is a matrix (MA) protein (p17). Below 
the matrix is the nucleoprotein made up of a capsid (CA) 
protein (p24, p25). Inside the cores are various cone-
shaped nucleocapsid proteins (p9, p7), as well as poly-
merase  enzyme  containing  reverse  transcriptase  (RT, 




p63), the protease (PR,p15) and the integrase (IN), p11 
(Levy, 1993). 
HIV is transmitted through blood products (including 
blood transfusions, intravenous drug abuse in sharing of 
needles, health care workers in needlestick  injuries and 
mucocutaneous exposures), organ transplants, sexual 
intercourse (both homosexual and heterosexual exposu-
res) and vertical transmission (10-40% of babies born of 
infected mother will be infected). Infection may occur in 
utero, during birth, post natally or through breast feeding. 
There is no evidence to suggest that HIV can be trans-
mitted by insects, casual contact (saliva, kissing) or by 
sharing of eating and drinking utensils (Brooks et al., 
2002). The virus enters the cell by fusing with the cell 
membrane. This event involves an interaction with a 
cellular receptor (the major one being CD4) followed by 
conformational changes in the viral envelope to permit 
virus-cell fusion. The latter may involve cleavage of the 
envelope gp120 by a cellular protease (Levy et al., 
1997).   
Clinical signs of acute (primary) HIV infection include: a 
red, slightly raised rash, lymphadenopathy, low or high-
grade fever, night sweats, pains in the eyes, throats and 
muscles, and general malaise. Some infected individuals 
develop gastrointestinal and neurological symptoms 
(Levy et al., 1997). Following the clinical manifestations 
of the primary infection, individuals can be asymptomatic 
for up to 10 years. After the initial infection there is gene-
rally a slow but steady decrease in CD4+ cell numbers, a 
parameter usually used to predict the onset of symp-
toms. The reason for the CD4+ cell loss could be as a 
result of direct HIV destruction of the cell, cytokine injury 
and immunological anti-cellular responses. When the 
CD4+ cell count in the blood (normally 1000) drops 
below 200 to 300 cells, clinical disorders such as 
infections and malignancies that can lead to death often 
appear. These diseases define the condition called 
AIDS. It is important to recognize that the virus itself 
does not directly cause these diseases; they result from 
HIV-induced immune destruction (Dunn et al., 1992). 
Gynaecolgical problems in women positive for the virus 
include chronic vaginal candidiasis, vaginitis, colpitis 
genital folliculitis and dermatitis, herpes genitalis, cervical 
atypia, chronic pelvic infection and menstrual abnormal-
lities (Adrian, 1992) 
AIDS is not curable but it can be prevented and given 
the massive social and economic implications of HIV 
infection and AIDS- related deaths, this study was desig-
ned to provide empirical evidence of prevalence among 
apparently healthy persons as well as to create aware-
ness as to the threat of HIV/AIDS and its possible conse-
quences to maternal and infant health in the Nigeria 
environment in order that appropriate steps could be 
taken to prevent any nosocomial infection. It will also 
expose the need to provide adequate medication to 






MATERIALS AND METHODS 
 
The study population 
 
The sample population included a total of ten thousand and thirty 
two pregnant women who attended the ante-natal clinic of 
Braithwaite Memorial Hospital, Port-Harcourt, Nigeria from the 
period of January 2000 to December 2004. The purpose of the 
study was fully explained to them (and their health care providers) 
and their informed consent obtained prior to the study as 
recommended by World Health Organization (TDR, 2002) 
 
 
Sampling procedure and HIV screening   
 
All blood samples sent to the HIV unit of the hospital laboratory 
with completed and certified forms from clinicians were processed 
by standard operating procedure to check for HIV among the 
pregnant women. The ELISA (enzyme-linked immunosorbent 
assay) test was commonly employed to screen the pregnant 
women, while the western blot method was used to confirm all 
positive cases. In the ELISA test (using ELISCAN HIV 1/2 from M/S 
Ranbaxy Diagnostics, New Delhi), the patients serum was added to 
a microplate well to which HIV antigens derived from HIV grown in 
human T lymphocytes have been attached. This mixture was then 
incubated for about 3 h. All antibodies to HIV present in the serum, 
bound to the HIV antigens. The plate was then washed to remove 
all other components of the serum. Subsequently an antihuman 
globulin together with an enzyme capable of altering a colour 
substrate were added and allowed to bind to the bound HIV 
antibody. Finally, the colour substrate was added. A colour change 
occurred if HIV antibody was present in the patients’ serum (Levy 
et al., 1997). The Western blot was the primary method used to 
confirm all positive cases. In the analysis (using Qualicode HIV 1/2 
from Immunetics Inc. USA), individual proteins of the HIV were 
separated by electrophoresis through a gel material. The proteins 
were then transferred (blotted) from the gel onto a nitrocellulose 
filter. The patient’s serum was added to the filter and any 
antibodies to HIV bind to the specific proteins. Enzyme-labelled 
antibodies to human immunoglobulin were then added. These 
bound to any anti-HIV antibodies that attached to the nitrocellulose 
filter after reacting with viral proteins. All un-bound antibodies and 
proteins were removed by rinsing the filter. Detection of the bound 
complex was revealed by adding a colourless substance that the 
antibody-bound enzyme converted to a colour product. The “3 band 
rule” was used to interprete the result of the western blot 
procedure. If no viral bands were detected, the result was consi-
dered negative. Results were interpreted as positive if bands 
appeared at the site of two or more of the following HIV antigens: 
p24, gp41 or gp120. The test was considered indeterminate if 
fewer than two of bands were present (Mckane and Kandel, 1996).          
 
 
RESULT AND DISCUSSION 
 
Table 1 presents the annual distribution of HIV among 
pregnant women attending Braithwaite memorial Hospital 
Port-Harcourt, Nigeria between January 2000 and recor-
ded in year 2001 with 138 (1.38%), followed by Decem-
ber 2004. A total of 595 (5.93%) pregnant women tested 
positive to the virus. The highest cases were 2004 with 
135 (1.36%). The least cases were recorded in year 
2000 with 89 (0.89%). There was no significant differ-
ence (P < 0.5) in the prevalence of HIV between 2001 
through  year 2004. However a noticeable significant diff- 




Table 1. Annual distribution of HIV among pregnant women attending Braithwaite Memorial Hospital, 
Port Harcourt, Nigeria. 
 
Year Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec Total 
2000 21 4 6 7 3 2 15 10 3 12 3 1 89 
2001 8 15 13 25 5 1 9 7 16 2 23 14 138 
2002 16 1 7 4 1 11 20 12 2 5 9 24 112 
2003 5 4 8 1 22 12 2 17 16 6 12 16 121 
2004 18 9 7 7 1 1 7 6 13 14 16 26 135 




Table 2. Age distribution of HIV prevalence among pregnant women in Braithwaite Memorial 
Hospital, Port-Harcourt, Nigeria. 
 




HIV positive HIV negative 
Within grp Within  pop 
15-20 519 50 469 9.63 0.50 
21-25 3,762 180 3,582 4.78 1.75 
26-30 3,820 120 3,700 3.14 1.20 
31-35 480 100 380 20.83 1.00 
36-40 1,441 137 1,304 9.51 1.37 
41-45 10 8 2 80 0.08 




erence (P < 0.5) occurred between the year 2000 and 
other years. A greater number (81) of the pregnant 
women were diagnosed of HIV in the months of Decem-
ber representing 0.81% and January (68) representing 
0.68% while the least cases (33) were diagnosed in the 
months of February representing 0.33% and May with 
(32) representing 0.32% cases during the period of 
study. 
Table 2 shows the age distribution of HIV among the 
pregnant women. A significantly higher number of the 
infected women fall in the age bracket of 41-45 years 
(80%) even though this age bracket had the least sample 
size of 10; while the least prevalence occurred in the age 
group of  26-30 (3.14%) inspite  of the fact that  the age 
group had the largest sample size.  
While the prevalence rate was low in year 2000, there 
were significant increases in the prevalence as the year 
progressed. It is possible that in year 2000, enough 
public awareness had not yet been created about the 
threat of HIV/AIDS, so some of the women escaped 
proper screening. Similarly, there was high prevalence in 
the months of December and January. This may be 
associated with the seasons of Christmas and New Year 
when many women indulge in commercial sex business 
to provide life’s necessities for their families. From Table 
2, it will be observed that the age group of 26-30 had the 
least prevalence (3.14%) despite the high number 
screened. This is followed by 21-25 (4.78%). These age 
groups were made up, mostly of newly married women, 
who may be presumed to still be in their “honeymoon” 
and therefore very faithful to their husbands. However 
the same may not be said of women aged 41-45 years 
where, despite the low number screened, the prevalence 
rate was high (80%) enough. This could be due to the 
fact that the women in this group are more exposed to 
the risk factors that predispose to the infection. The fact 
that the age group of 15-20 (teenagers) had a relatively 
low prevalence (9.63%) could mean that the Nigerian 
governments widely - publicized anti-AIDS campaign 
urging them to ‘zip-up’ till marriage is yielding positive 
results. 
Infection with HIV represents something of an 
immunological paradox, in that HIV induces a strong 
antiviral immune response, whilst simultaneously and 
progressively disrupting the ability of the immune system 
to respond to new infections and antigens, ultimately 
leading to severe immune deficient of the cell-mediated 
immune system (Browning, 1996). HIV, unlike other 
viruses has a unique ability to escape detection by the 
immune system (McMichael, 1996). This is however 
made possible by the replication machinery of the virus 
which is so inaccurate that it generates new mutants for 
virtually every virion produced in an infected individual, 
thus, creating a myriad of new and unique viral particles 
every day. These mutant viruses keep continually dama-
ging or killing the cells of the immune system (mainly 
CD4+ lymphocytes) and, thus progressively destroy the 
body’s  ability  to fight opportunistic infections and certain   




cancers resulting in AIDS and finally death in 7 to 10 
years (Mahender, 2006).      
Seropositive women or women with seropositive sex-
ual partners are at increased risk of acquiring AIDS. If 
they become pregnant, their offsprings are also at high 
risk of acquiring AIDS (Brooks et al., 2002). In a recent 
study, Pietro et al. (2006) confirmed that occult hepatitis 
B virus (HBV) infection which we (Obi et al., 2006) found 
to be highly prevalent among pregnant women in Nigeria, 
could be reactivated by infection of HIV. 
AIDS is neither water borne disease nor an air borne 
but a problem deeply rooted in peoples’ life style. In an 
attempt to support the effort of our government and 
indeed other global organizations and governments in 
combating the menace of HIV/AIDS, we hereby recom-
mend that since HIV cannot be detected (“AIDS no dey 
show for face”) except one is screened for it; every one 
must be screened to establish their HIV status. Any one 
ignorant of his/her HIV status should be assumed posi-
tive until proved otherwise through HIV screening. Any 
sexual intercourse (outside of mutually monogamous HIV 
antibody-negative relationships) should be protected by a 
condom. All unmarried people should abstain totally from 
sexual intercourse. The sharing of needles and syringes 
must be avoided. All blood for transfusion purposes must 
be screened for the presence of the HIV 1 and HIV 2 
antigens. Health care personnel must adhere strictly to 
infection-control guidelines. All women who have been 
potentially exposed should seek HIV antibody testing be-
fore becoming pregnant and if the test is positive should 
consider avoiding pregnancy. HIV infected mothers 
should avoid breast feeding to reduce the risk of trans-
mission of the virus to their children. Adequate care, 
counseling and management of those already infected 
i.e. people living with HIV/AIDS (PLWHA). And finally, 
the government at all levels should create employment 
opportunities so that those driven into commercial sex 
business due to poverty could have an alternative and 
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